H.C. Wainwright lowered the firm’s price target on Biomea Fusion (BMEA) to $18 from $40 and keeps a Buy rating on the shares following the Q1 report. The firm removed removing type 1 diabetes from its projections and purged out the projected launch years for icovamenib in type 2 to 2031 from 2029.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion reports Q1 EPS (80c), consensus (60c)
- Biomea Fusion price target lowered to $3 from $11 at Barclays
- Biomea Fusion’s Strategic Shift: A Year of Transformation
- Biomea Fusion reports Q4 EPS (81c), consensus (93c)
- Buy Rating for Biomea Fusion’s Icovamenib: A Promising Breakthrough in Diabetes Treatment